Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
5.85M
-
Number of holders
-
13
-
Total 13F shares, excl. options
-
723K
-
Shares change
-
+717K
-
Total reported value, excl. options
-
$528K
-
Value change
-
+$524K
-
Number of buys
-
12
-
Number of sells
-
-1
-
Price
-
$0.73
Significant Holders of CERO THERAPEUTICS HOLDINGS, INC. - Common Stock, par value $0.0001 per share (CERO) as of Q1 2025
13 filings reported holding CERO - CERO THERAPEUTICS HOLDINGS, INC. - Common Stock, par value $0.0001 per share as of Q1 2025.
CERO THERAPEUTICS HOLDINGS, INC. - Common Stock, par value $0.0001 per share (CERO) has 13 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 723K shares
of 5.85M outstanding shares and own 12.35% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (312K shares), Parallel Advisors, LLC (220K shares), Avantax Planning Partners, Inc. (74.3K shares), UBS Group AG (42.7K shares), ARCH Venture Management, LLC (22.1K shares), GEODE CAPITAL MANAGEMENT, LLC (16.9K shares), CITADEL ADVISORS LLC (16.2K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (13.3K shares), Tower Research Capital LLC (TRC) (5.02K shares), and SBI Securities Co., Ltd. (110 shares).
This table shows the top 13 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.